2663 related articles for article (PubMed ID: 7675773)
41. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics.
Momand J; Zambetti GP
Oncogene; 1996 Jun; 12(11):2279-89. PubMed ID: 8649767
[TBL] [Abstract][Full Text] [Related]
42. Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas.
Seki A; Kodama J; Miyagi Y; Kamimura S; Yoshinouchi M; Kudo T
Int J Cancer; 1997 Sep; 73(1):33-7. PubMed ID: 9334806
[TBL] [Abstract][Full Text] [Related]
43. p53 and PCNA expression in malignant melanomas of the head and neck.
Girod SC; Groth W; Junk M; Gerlach KL
Pigment Cell Res; 1994 Oct; 7(5):354-7. PubMed ID: 7886008
[TBL] [Abstract][Full Text] [Related]
44. mdm-2 expression in human testicular germ-cell tumors and its clinical value.
Eid H; Institoris E; Géczi L; Bodrogi I; Bak M
Anticancer Res; 1999; 19(4C):3485-90. PubMed ID: 10629640
[TBL] [Abstract][Full Text] [Related]
45. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance.
Haidar MA; El-Hajj H; Bueso-Ramos CE; Manshouri T; Glassman A; Keating MJ; Maher A
Am J Hematol; 1997 Mar; 54(3):189-95. PubMed ID: 9067496
[TBL] [Abstract][Full Text] [Related]
46. Expression of mdm-2 protein in neoplastic, preneoplastic, and normal bronchial mucosa specimens: comparative study with p53 expression.
Rasidakis A; Orphanidou D; Kalomenidis J; Papamichalis G; Toumbis M; Lambaditis J; Sacharidou A; Papastamatiou H; Jordanoglou J
Hybridoma; 1998 Aug; 17(4):339-45. PubMed ID: 9790068
[TBL] [Abstract][Full Text] [Related]
47. Expression of mdm-2 oncoprotein in the primary and metastatic sites of mammary tumor (GI-101) implanted athymic nude mice.
Rathinavelu P; Malavé A; Raney SR; Hurst J; Roberson CT; Rathinavelu A
Cancer Biochem Biophys; 1999 Jul; 17(1-2):133-46. PubMed ID: 10738909
[TBL] [Abstract][Full Text] [Related]
48. MDM-2 protein is expressed in different layers of normal human skin.
Dazard JE; Augias D; Neel H; Mils V; Marechal V; Basset-Séguin N; Piette J
Oncogene; 1997 Mar; 14(9):1123-8. PubMed ID: 9070662
[TBL] [Abstract][Full Text] [Related]
49. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.
Polsky D; Bastian BC; Hazan C; Melzer K; Pack J; Houghton A; Busam K; Cordon-Cardo C; Osman I
Cancer Res; 2001 Oct; 61(20):7642-6. PubMed ID: 11606406
[TBL] [Abstract][Full Text] [Related]
50. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay CA
Mol Cell Biol; 1993 Jan; 13(1):301-6. PubMed ID: 8417333
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor.
de Souza PE; Paim JF; Carvalhais JN; Gomez RS
J Oral Pathol Med; 1999 Feb; 28(2):54-8. PubMed ID: 9950250
[TBL] [Abstract][Full Text] [Related]
52. Morphologic changes and altered gene expression in an epithelioid hemangioendothelioma during a ten-year course of disease.
Theurillat JP; Vavricka SR; Went P; Weishaupt D; Perren A; Leonard-Meier C; Bachli EB
Pathol Res Pract; 2003; 199(3):165-70. PubMed ID: 12812318
[TBL] [Abstract][Full Text] [Related]
53. p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas.
Pacinda SJ; Ledet SC; Gondo MM; Langston C; Brown RW; Carmona PA; Franklin RB; Roggli VL; Cagle PT
Hum Pathol; 1996 Jun; 27(6):542-6. PubMed ID: 8666362
[TBL] [Abstract][Full Text] [Related]
54. Protein expression of Mdm2 and p53 in hyperplastic and neoplastic lesions of the canine circumanal gland.
Nakano M; Taura Y; Inoue M
J Comp Pathol; 2005 Jan; 132(1):27-32. PubMed ID: 15629477
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance.
Loggini B; Rinaldi I; Pingitore R; Cristofani R; Castagna M; Barachini P
Tumori; 2001; 87(3):179-86. PubMed ID: 11504374
[TBL] [Abstract][Full Text] [Related]
56. HDM2 protein overexpression and prognosis in primary malignant melanoma.
Polsky D; Melzer K; Hazan C; Panageas KS; Busam K; Drobnjak M; Kamino H; Spira JG; Kopf AW; Houghton A; Cordon-Cardo C; Osman I
J Natl Cancer Inst; 2002 Dec; 94(23):1803-6. PubMed ID: 12464652
[TBL] [Abstract][Full Text] [Related]
57. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma.
Lynch BJ; Komaromy-Hiller G; Bronstein IB; Holden JA
Hum Pathol; 1998 Nov; 29(11):1240-5. PubMed ID: 9824101
[TBL] [Abstract][Full Text] [Related]
58. mdm-2 oncogene expression in non-Hodgkin's lymphomas.
Kawamata N; Miller C; Levy V; Shintaku IP; Koeffler HP; Said JW
Diagn Mol Pathol; 1996 Mar; 5(1):33-8. PubMed ID: 8919543
[TBL] [Abstract][Full Text] [Related]
59. Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components.
Radhi JM
J Cutan Med Surg; 1999 Oct; 3(6):293-7. PubMed ID: 10575157
[TBL] [Abstract][Full Text] [Related]
60. Immunoreactivity of new antibodies anti-p53 and anti-MDM-2 in paraffin embedded tissue samples.
Andrejco M; Kaláb M; Oulton A; Kolár Z; Lichnovský V; Kod'ousek R; Vojtĕsek B
Acta Univ Palacki Olomuc Fac Med; 1996; 140():63-7. PubMed ID: 9431695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
